Alkermes plc
US ˙ NasdaqGS ˙ IE00B56GVS15

Introduction

This page provides a comprehensive analysis of the known insider trading history of Nancy Lurker. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Nancy Lurker has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:EYPT / EyePoint Pharmaceuticals, Inc. Director 216,547
US:ALKS / Alkermes plc Director 10,705
US:COLL / Collegium Pharmaceutical, Inc. Director 22,517
US:AQST / Aquestive Therapeutics, Inc. Director 20,000
US:MNK / Mallinckrodt PLC Director 10,507
US:PDII / PDI, Inc. CEO, Director 871,681
US:AUXL / Auxilium Pharmaceuticals Inc Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Nancy Lurker. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ALKS / Alkermes plc - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ALKS / Alkermes plc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ALKS / Alkermes plc Insider Trades
Insider Sales ALKS / Alkermes plc - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ALKS / Alkermes plc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ALKS / Alkermes plc Insider Trades
Insider Purchases AQST / Aquestive Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ALKS / Alkermes plc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AQST / Aquestive Therapeutics, Inc. Insider Trades
Insider Sales AQST / Aquestive Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ALKS / Alkermes plc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AQST / Aquestive Therapeutics, Inc. Insider Trades
Insider Purchases COLL / Collegium Pharmaceutical, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ALKS / Alkermes plc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

COLL / Collegium Pharmaceutical, Inc. Insider Trades
Insider Sales COLL / Collegium Pharmaceutical, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ALKS / Alkermes plc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

COLL / Collegium Pharmaceutical, Inc. Insider Trades
Insider Purchases EYPT / EyePoint Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ALKS / Alkermes plc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2024-08-16 EYPT Lurker Nancy 3,173 7.8800 3,173 7.8800 25,003 73 12.1200 13,454 53.81
2020-03-10 EYPT Lurker Nancy 98,000 1.0615 9,800 10.6150 104,027
2019-03-29 EYPT Lurker Nancy 28,500 1.7630 2,850 17.6300 50,246
2017-06-14 PSDV Lurker Nancy 56,700 1.7630 56,700 1.7630 99,962

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EYPT / EyePoint Pharmaceuticals, Inc. Insider Trades
Insider Sales EYPT / EyePoint Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ALKS / Alkermes plc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2024-01-24 EYPT Lurker Nancy 29,956 24.9783 29,956 24.9783 748,250 341 7.0200 -537,958 -71.90
2024-01-23 EYPT Lurker Nancy 5,044 24.9702 5,044 24.9702 125,950
2023-12-04 EYPT Lurker Nancy 20,000 20.7600 20,000 20.7600 415,200

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EYPT / EyePoint Pharmaceuticals, Inc. Insider Trades
Insider Purchases IDXG / Interpace Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ALKS / Alkermes plc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2014-11-10 PDII Lurker Nancy 16,000 1.6931 16,000 1.6931 27,090 252
2014-11-07 PDII Lurker Nancy 33,000 1.7728 33,000 1.7728 58,502
2014-11-06 PDII Lurker Nancy 1,000 1.6000 1,000 1.6000 1,600
2014-11-05 PDII Lurker Nancy 27,500 1.7359 27,500 1.7359 47,737
2014-11-05 PDII Lurker Nancy 27,500 1.7483 27,500 1.7483 48,078
2014-11-05 PDII Lurker Nancy 500 1.7200 500 1.7200 860
2014-11-05 PDII Lurker Nancy 500 1.7199 500 1.7199 860

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IDXG / Interpace Biosciences, Inc. Insider Trades
Insider Sales IDXG / Interpace Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ALKS / Alkermes plc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IDXG / Interpace Biosciences, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Nancy Lurker as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-07-11 2025-07-10 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 11,111 216,547 5.41
2025-06-02 2025-05-31 4 ALKS Alkermes plc.
Ordinary Shares
F - Taxes -1,924 10,705 -15.23 30.61 -58,894 327,680
2025-06-02 2025-05-31 4 ALKS Alkermes plc.
Ordinary Shares
M - Exercise 8,013 12,629 173.59
2025-05-19 2025-05-15 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
A - Award 9,791 22,517 76.94
2025-04-14 2025-04-11 4 ALKS Alkermes plc.
Ordinary Shares
F - Taxes -901 4,616 -16.33 27.00 -24,327 124,632
2025-04-14 2025-04-11 4 ALKS Alkermes plc.
Ordinary Shares
M - Exercise 3,752 5,517 212.58
2025-04-14 2025-04-11 4 ALKS Alkermes plc.
Ordinary Shares
F - Taxes -558 1,765 -24.02 27.00 -15,066 47,655
2025-04-14 2025-04-11 4 ALKS Alkermes plc.
Ordinary Shares
M - Exercise 2,323 2,323
2025-02-11 2025-02-09 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 20,000 205,436 10.79
2025-02-05 2025-02-04 4 COLL COLLEGIUM PHARMACEUTICAL, INC
Common Stock
A - Award 12,726 12,726
2025-01-07 2025-01-06 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 75,134 185,436 68.12
2025-01-07 2025-01-05 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 12,667 110,302 12.97
2024-08-20 2024-08-16 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
P - Purchase 3,173 97,635 3.36 7.88 25,003 769,364
2024-07-12 2024-07-10 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 11,111 94,462 13.33
2024-02-13 2024-02-13 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
G - Gift 74,681 126,889 143.05
2024-02-13 2024-02-13 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
G - Gift -74,681 83,351 -47.26
2024-02-13 2024-02-09 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
F - Taxes -6,981 158,032 -4.23 28.80 -201,053 4,551,322
2024-02-13 2024-02-09 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
F - Taxes -7,962 165,013 -4.60 28.80 -229,306 4,752,374
2024-02-13 2024-02-09 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 17,534 172,975 11.28
2024-02-13 2024-02-09 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 20,000 155,441 14.77
2024-01-25 2024-01-24 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
S - Sale -29,956 135,441 -18.11 24.98 -748,250 3,383,086
2024-01-25 2024-01-23 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
S - Sale -5,044 165,397 -2.96 24.97 -125,950 4,129,996
2024-01-09 2024-01-06 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
F - Taxes -23,043 170,441 -11.91 20.40 -470,077 3,476,996
2024-01-09 2024-01-06 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 75,133 193,484 63.48
2024-01-03 2023-12-28 4/A EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
G - Gift 52,208 52,208
2024-01-03 2023-12-28 4/A EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
G - Gift -52,208 118,351 -30.61
2023-12-06 2023-12-04 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
S - Sale -20,000 170,559 -10.50 20.76 -415,200 3,540,805
2023-02-13 2023-02-09 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 20,000 190,559 11.73
2023-02-13 2023-02-09 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 17,533 170,559 11.46
2022-03-02 2022-02-28 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -12,466 0 -100.00
2022-03-02 2022-02-28 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 12,466 150,281 9.05
2022-02-23 2022-02-21 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -13,717 13,718 -50.00
2022-02-23 2022-02-21 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 13,717 137,815 11.05
2022-02-11 2022-02-09 4 EYPT EyePoint Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 240,000 240,000
2022-02-11 2022-02-09 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 60,000 60,000
2022-02-11 2022-02-09 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -17,533 35,067 -33.33
2022-02-11 2022-02-09 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 17,533 124,098 16.45
2021-11-17 2021-11-15 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
S - Sale X -10,000 103,546 -8.81 20.15 -201,480 2,086,245
2021-06-23 2021-06-22 4 EYPT EyePoint Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 213,700 213,700
2021-06-23 2021-06-22 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 52,600 52,600
2021-06-17 2021-06-15 4 AQST Aquestive Therapeutics, Inc.
Stock Option (Right to Purchase)
A - Award 20,000 20,000
2021-06-15 2021-06-14 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -4,500 0 -100.00
2021-06-15 2021-06-14 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 4,500 113,546 4.13
2021-03-02 2021-02-28 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -12,467 12,466 -50.00
2021-03-02 2021-02-28 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 12,467 109,046 12.91
2021-02-23 2021-02-21 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -13,717 13,718 -50.00
2021-02-23 2021-02-21 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 13,717 96,579 16.55
2021-02-11 2020-06-15 5 EYPT EyePoint Pharmaceuticals, Inc.
Stock Option (Right to Buy)
G - Gift 27,132 27,132
2021-02-11 2020-06-15 5 EYPT EyePoint Pharmaceuticals, Inc.
Stock Option (Right to Buy)
G - Gift -27,132 65,868 -29.17
2021-02-11 2020-06-15 5 EYPT EyePoint Pharmaceuticals, Inc.
Stock Option (Right to Buy)
G - Gift 18,000 18,000
2021-02-11 2020-06-15 5 EYPT EyePoint Pharmaceuticals, Inc.
Stock Option (Right to Buy)
G - Gift -18,000 36,000 -33.33
2021-02-11 2020-06-15 5 EYPT EyePoint Pharmaceuticals, Inc.
Stock Option (Right to Buy)
G - Gift 16,000 16,000
2021-02-11 2020-06-15 5 EYPT EyePoint Pharmaceuticals, Inc.
Stock Option (Right to Buy)
G - Gift -16,000 8,000 -66.67
2021-02-11 2020-06-15 5 EYPT EyePoint Pharmaceuticals, Inc.
Stock Option (Right to Buy)
G - Gift 63,750 63,750
2021-02-11 2020-06-15 5 EYPT EyePoint Pharmaceuticals, Inc.
Stock Option (Right to Buy)
G - Gift -63,750 21,250 -75.00
2020-07-02 2020-06-30 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -124,667 249,333 -33.33
2020-07-02 2020-06-30 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 124,667 784,467 18.89
2020-06-30 2020-06-27 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -40,000 0 -100.00
2020-06-30 2020-06-27 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 40,000 659,800 6.45
2020-06-18 2020-06-16 4 AQST Aquestive Therapeutics, Inc.
Stock Option (Right to Purchase)
A - Award 14,000 14,000
2020-06-16 2020-06-14 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -45,000 45,000 -50.00
2020-06-16 2020-06-14 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 45,000 619,800 7.83
2020-03-11 2020-03-10 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
P - Purchase 98,000 574,800 20.55 1.06 104,027 610,150
2020-03-03 2020-02-28 4 EYPT EyePoint Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 748,000 748,000
2020-03-03 2020-02-28 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 374,000 374,000
2020-02-25 2020-02-21 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -137,174 274,349 -33.33
2020-02-25 2020-02-21 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 137,174 476,800 40.39
2019-10-15 2019-10-12 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
F - Taxes -10,745 314,455 -3.30 2.10 -22,618 661,928
2019-06-28 2019-06-27 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -40,000 40,000 -50.00
2019-06-28 2019-06-27 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 40,000 325,200 14.03
2019-06-27 2019-06-25 4 EYPT EyePoint Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 930,000 930,000
2019-06-27 2019-06-25 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 411,523 411,523
2019-06-17 2019-06-13 4 AQST Aquestive Therapeutics, Inc.
Stock Option (Right to Purchase)
A - Award 13,350 13,350
2019-06-17 2019-06-14 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -45,000 90,000 -33.33
2019-06-17 2019-06-14 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 45,000 285,200 18.73
2019-04-01 2019-03-29 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
P - Purchase 28,500 240,200 13.46 1.76 50,246 423,473
2018-10-16 2018-10-12 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
A - Award 76,667 211,700 56.78
2018-07-26 2018-07-24 4 AQST Aquestive Therapeutics, Inc.
Stock Option (Right to Purchase)
A - Award 26,700 26,700
2018-06-29 2018-06-27 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
M - Exercise -40,000 80,000 -33.33
2018-06-29 2018-06-27 4 EYPT EyePoint Pharmaceuticals, Inc.
Common Stock
M - Exercise 40,000 135,033 42.09
2018-06-18 2018-06-14 4 EYPT EyePoint Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 540,000 540,000
2018-06-18 2018-06-14 4 EYPT EyePoint Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 135,000 135,000
2018-03-21 2018-03-19 4 PSDV pSivida Corp.
Common stock
A - Award 38,333 95,033 67.61
2017-12-19 2017-12-15 4 PSDV pSivida Corp.
Stock Option (right to buy)
A - Award 240,000 240,000
2017-12-19 2017-12-15 4 PSDV pSivida Corp.
Restricted Stock Units
A - Award 120,000 120,000
2017-06-14 2017-06-14 4 PSDV pSivida Corp.
Common Stock
P - Purchase 56,700 56,700 1.76 99,962 99,962
2016-12-14 2016-12-12 4 PSDV pSivida Corp.
Employee Stock Option (right to buy)
A - Award 850,000 850,000
2016-03-18 2016-03-16 4 MNK Mallinckrodt plc
Ordinary Shares
F - Taxes -458 10,507 -4.18 55.69 -25,506 585,135
2016-03-18 2016-03-16 4 MNK Mallinckrodt plc
Ordinary Shares
A - Award 4,041 10,965 58.36
2015-03-23 2015-03-19 4 MNK Mallinckrodt plc
Ordinary Shares
A - Award 1,715 6,924 32.92
2015-03-09 2015-03-05 4 PDII PDI INC
Common Stock
A - Award 444,364 871,681 103.99 1.73 768,750 1,508,008
2015-01-30 2015-01-29 4 AUXL AUXILIUM PHARMACEUTICALS INC
Nonqualified Stock Option (Right to Buy)
J - Other -5,000 0 -100.00 36.53 -182,650
2015-01-30 2015-01-29 4 AUXL AUXILIUM PHARMACEUTICALS INC
Common Stock
J - Other -10,000 0 -100.00 36.53 -365,300
2014-12-08 2014-12-05 4 AUXL AUXILIUM PHARMACEUTICALS INC
Nonqualified Stock Option (Right to Buy)
M - Exercise -5,000 0 -100.00
2014-12-08 2014-12-05 4 AUXL AUXILIUM PHARMACEUTICALS INC
Nonqualified Stock Option (Right to Buy)
M - Exercise -5,000 0 -100.00
2014-12-08 2014-12-05 4 AUXL AUXILIUM PHARMACEUTICALS INC
Nonqualified Stock Option (Right to Buy)
M - Exercise -15,000 0 -100.00
2014-12-08 2014-12-05 4 AUXL AUXILIUM PHARMACEUTICALS INC
Common Stock
S - Sale -7,430 10,000 -42.63 34.00 -252,620 340,000
2014-12-08 2014-12-05 4 AUXL AUXILIUM PHARMACEUTICALS INC
Common Stock
S - Sale -25,000 17,430 -58.92 34.00 -850,000 592,620
2014-12-08 2014-12-05 4 AUXL AUXILIUM PHARMACEUTICALS INC
Common Stock
M - Exercise 5,000 42,430 13.36 14.37 71,850 609,719
2014-12-08 2014-12-05 4 AUXL AUXILIUM PHARMACEUTICALS INC
Common Stock
M - Exercise 5,000 37,430 15.42 24.62 123,100 921,527
2014-12-08 2014-12-05 4 AUXL AUXILIUM PHARMACEUTICALS INC
Common Stock
M - Exercise 15,000 32,430 86.06 19.78 296,700 641,465
2014-11-12 2014-11-10 4 PDII PDI INC
Common Stock
P - Purchase 16,000 533,317 3.09 1.69 27,090 902,959
2014-11-12 2014-11-07 4 PDII PDI INC
Common Stock
P - Purchase 33,000 517,317 6.81 1.77 58,502 917,100
2014-11-07 2014-11-06 4 PDII PDI INC
Common Stock
P - Purchase 1,000 490,403 0.20 1.60 1,600 784,645
2014-11-07 2014-11-05 4 PDII PDI INC
Common Stock
P - Purchase 500 489,403 0.10 1.72 860 841,724
2014-11-07 2014-11-05 4 PDII PDI INC
Common Stock
P - Purchase 500 488,903 0.10 1.72 860 840,913
2014-11-07 2014-11-05 4 PDII PDI INC
Common Stock
P - Purchase 27,500 488,403 5.97 1.75 48,078 853,875
2014-11-07 2014-11-05 4 PDII PDI INC
Common Stock
P - Purchase 27,500 460,903 6.35 1.74 47,737 800,082
2014-05-27 2014-05-22 4 MNK Mallinckrodt plc
Ordinary Shares
A - Award 572 5,209 12.34
2014-05-22 2014-05-21 4 AUXL AUXILIUM PHARMACEUTICALS INC
Nonqualified Stock Option (Right to Buy)
A - Award 5,000 5,000
2014-05-22 2014-05-21 4 AUXL AUXILIUM PHARMACEUTICALS INC
Common Stock
A - Award 5,000 17,430 40.23
2014-03-27 2014-03-25 4 PDII PDI INC
Common Stock
F - Taxes -23,316 433,403 -5.11 4.91 -114,482 2,128,009
2014-03-24 2014-03-20 4 MNK Mallinckrodt plc
Ordinary Shares
F - Taxes -971 4,637 -17.31 69.95 -67,921 324,358
2014-03-24 2014-03-20 4 MNK Mallinckrodt plc
Ordinary Shares
A - Award 2,574 5,608 84.84
2014-02-28 2014-02-26 4 PDII PDI INC
Stock Appreciation Rights
A - Award 188,165 678,116 38.40
2014-02-28 2014-02-26 4 PDII PDI INC
Stock Appreciation Rights
A - Award 177,665 489,951 56.89
2014-02-28 2014-02-26 4 PDII PDI INC
Common Stock
A - Award 63,177 456,719 16.05 5.10 322,203 2,329,267
2014-02-28 2014-02-26 4 PDII PDI INC
Common Stock
A - Award 10,584 393,542 2.76 5.10 53,978 2,007,064
2013-07-22 2013-07-18 4 MNK Mallinckrodt plc
Ordinary Shares
A - Award 3,034 3,034
2013-05-03 2013-05-01 4 AUXL AUXILIUM PHARMACEUTICALS INC
Nonqualified Stock Option (Right to Buy)
A - Award 5,000 5,000
2013-05-03 2013-05-01 4 AUXL AUXILIUM PHARMACEUTICALS INC
Common Stock
A - Award 5,000 12,430 67.29
2013-04-08 2013-04-04 4 PDII PDI INC
Stock Appreciation Rights
A - Award 141,700 592,286 31.45
2013-04-08 2013-04-04 4 PDII PDI INC
Common Stock
A - Award 51,320 382,958 15.47 5.44 279,181 2,083,292
2013-03-05 2013-03-01 4 PDII PDI INC
Common Stock
F - Taxes -16,279 331,638 -4.68 7.43 -120,953 2,464,070
2012-07-03 2012-06-29 4 AUXL AUXILIUM PHARMACEUTICALS INC
Common Stock
A - Award 417 7,430 5.95 26.89 11,213 199,793
2012-06-22 2012-06-21 4 AUXL AUXILIUM PHARMACEUTICALS INC
Nonqualified Stock Option (Right to Buy)
A - Award 5,000 5,000
2012-06-22 2012-06-21 4 AUXL AUXILIUM PHARMACEUTICALS INC
Common Stock
A - Award 5,000 7,013 248.39
2012-04-03 2012-03-30 4 AUXL AUXILIUM PHARMACEUTICALS INC
Common Stock
A - Award 605 2,013 42.97 18.57 11,235 37,381
2012-02-01 2012-01-31 4 PDII PDI INC
Stock Appreciation Rights
A - Award 111,684 450,586 32.95
2012-02-01 2012-01-31 4 PDII PDI INC
Common Stock
A - Award 50,702 347,917 17.06 6.41 325,000 2,230,148
2012-01-04 2011-12-30 4 AUXL AUXILIUM PHARMACEUTICALS INC
Common Stock
A - Award 563 1,408 66.63 19.93 11,221 28,061
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)